nei THIS MONTH IN
PSYCHOPHARMACOLOGY
FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders. The Reset device contains a patient application and a clinician dashboard and delivers cognitive behavioral therapy (CBT) to patients to teach them skills that can help them maintain abstinence. The application is intended to be used in conjunction with outpatient therapy to treat alcohol, cocaine, marijuana, and stimulant use disorders; it is not meant to be used for opioid dependence. It is indicated as a prescription-only adjunct treatment for patients with substance use disorders who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or whose primary substance of abuse is not opioids.


FDA Press Release